- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05826457
North American Prodromal Synucleinopathy Consortium Stage 2 (NAPS2)
Study Overview
Status
Detailed Description
REM sleep behavior disorder (RBD) is a disorder where people act out their dreams. People with RBD often, but not always, develop Parkinson's Disease, dementia with Lewy bodies, multiple system atrophy, or other neurodegenerative diseases of the synucleinopathy type.
The North American Prodromal Synucleinopathy Consortium Stage 2 (NAPS2) was formed with the purpose of enrolling participants with RBD, in anticipation of a future clinical trial of a neuroprotective trreatment against synucleinopathies. The NAPS Consortium will collect standardized clinical assessments, biofluids, and neuroimaging data. The RBD group will also undergo two overnight sleep studies. Some of this data will be used to develop biomarkers for synucleinopathies in the prodromal (presymptomatic) stage as well as a trial-ready registry of participants.
RBD group procedures include a clinical assessment, questionnaires, blood draw, neuroimaging (MRI and DaTscan), polysomnogram (sleep study), and optional lumbar puncture.
Control group procedures include a clinical assessment, questionnaires, blood draw, neuroimaging (MRI), and lumbar puncture.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Jennifer McLeland, PhD
- Phone Number: 314-747-3819
- Email: mclelandj@wustl.edu
Study Contact Backup
- Name: Leah Taylor
- Phone Number: 314-747-7297
- Email: ltaylor24@wustl.edu
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada, H4A 3J1
- Recruiting
- McGill University Health Centre Research Institute
-
Contact:
- Amelie Pelletier, PhD
- Phone Number: 2528 514-338-2222
- Email: amelie.pellletier@mail.mcgill.ca
-
Principal Investigator:
- Ron Postuma, MD
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- Not yet recruiting
- University of California Los Angeles
-
Contact:
- Adreanne Rivera
- Phone Number: 310-794-0213
- Email: UCLAnaps@mednet.ucla.edu
-
Principal Investigator:
- Alon Avidan, MD, MPH
-
Redwood City, California, United States, 94063
- Not yet recruiting
- Stanford University
-
Principal Investigator:
- Mitch Miglis, MD
-
Contact:
- Jordan Seliger
- Phone Number: 650-460-9260
- Email: jseliger@stanford.edu
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory University
-
Contact:
- Amanda Goodwin
- Email: amanda.christine.goodwin@emory.edu
-
Principal Investigator:
- Dan Huddleston, MD
-
Principal Investigator:
- Don Bliwise, PhD
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02145
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Amy Wang
- Email: jwang133@mgh.harvard.edu
-
Principal Investigator:
- Aleks Videnovic, MD, MSc
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55414
- Recruiting
- University of Minnesota
-
Contact:
- Carly Schroeder, BS
- Phone Number: 612-626-6499
- Email: schroedc@umn.edu
-
Principal Investigator:
- Michael Howell, MD
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic Rochester
-
Contact:
- Ruth Kraft
- Phone Number: 507-422-9780
- Email: rbd@mayo.edu
-
Principal Investigator:
- Brad Boeve, MD
-
Principal Investigator:
- Erik St. Louis, MD
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Contact:
- Maggie Zangrilli
- Phone Number: 314-362-0828
- Email: zangrillim@wustl.edu
-
Contact:
- Jennifer McLeland, PhD
- Phone Number: 314-747-3819
- Email: mclelandj@wustl.edu
-
Principal Investigator:
- Yo-El Ju, MD, MCSI
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- Oregon Health Sciences University
-
Principal Investigator:
- Miranda Lim, MD, PhD
-
Contact:
- Laura Dennis
- Email: NAPS@ohsu.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria for RBD Group
- Polysomnogram-confirmed RBD by ICSD-3 criteria
- Capable of providing informed consent at time of study enrollment
- Age > 18 years
Exclusion Criteria for RBD Group
- Diagnosis of PD, dementia of any type, or MSA unless previous participant in NAPS1.
- Narcolepsy-associated RBD
- RBD secondary to any known cause except prodromal synucleinopathy.
- Participation in a clinical trial, except by specific permission by the Executive Committee
- In the opinion of the investigator, the individual has a clinically significant uncontrolled medical condition that would impede safe completion of the study protocol
Inclusion Criteria for Control Group
- Ability to provide written consent
- Age > 18 years
- Must meet age, sex, and race matching criteria per the Data Management and Statistical core recommendations for the site
- Must be willing to undergo all testing procedures, including neuroimaging and lumbar puncture.
- Normal capacity to perform complex activities of daily living independently based on informant or physician report
Exclusion Criteria for Control Group
- History of dream enactment behavior to suggest RBD
- Parkinsonism, MSA, dementia, or mild cognitive impairment
- Active central nervous system, systemic, psychiatric condition or use of psychoactive medication that would adversely affect cognitive, neuropsychiatric, motor, or autonomic functioning.
- Contraindications to complete MRI.
- Contraindications to lumbar puncture.
- Participation in a clinical trial, except by specific permission by the Executive Committee
- In the opinion of the investigator, the individual has a clinically significant uncontrolled medical condition that would impede safe completion of the study protocol
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
RBD Group
Clinical observation involving annual visits to a study site for up to 5 years.
|
Control Group
Clinical observation involving annual visits to a study site for up to 5 years.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prodromal Synucleinopathy Rating Scale
Time Frame: up to 5 years
|
Rating scale combining neurocognitive battery, motor, autonomic, olfaction, color vision functions.
Global score range 0-3, with higher score indicating greater symptoms of synucleinopathy.
|
up to 5 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Yo-El Ju, MD, MCSI, Washington University School of Medicine
- Principal Investigator: Brad Boeve, MD, Mayo Clinic
- Principal Investigator: Ron Postuma, MD, McGill University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Sleep Wake Disorders
- Neurocognitive Disorders
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Neurodegenerative Diseases
- Proteostasis Deficiencies
- Autonomic Nervous System Diseases
- Primary Dysautonomias
- Hypotension
- Parkinson Disease
- Mental Disorders
- Parasomnias
- Dementia
- Lewy Body Disease
- Multiple System Atrophy
- Shy-Drager Syndrome
- Synucleinopathies
- REM Sleep Behavior Disorder
- REM Sleep Parasomnias
Other Study ID Numbers
- 1234567
- U19AG071754 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain